SetPoint medical Secures $140M to Pioneer Neuroimmune Modulation for Autoimmune Diseases
Are you or a loved one battling the debilitating effects of rheumatoid arthritis (RA) or another autoimmune condition? A groundbreaking new therapy is on the horizon, fueled by a recent $140 million financing round for SetPoint Medical. This isn’t just another incremental improvement in treatment; it represents a fundamentally new approach – neuroimmune modulation – with the potential to redefine how we manage chronic autoimmune diseases.
SetPoint Medical, a leader in the development of innovative therapies for autoimmune conditions, has successfully closed a final $25 million tranche of its Series C funding and a considerable $115 million Series D round.This important investment was co-led by Elevage Medical Technologies and Ally bridge Group, signaling strong confidence in the company’s pioneering technology and future prospects.But what is neuroimmune modulation,and why is this funding so important? Let’s delve into the details.
The promise of Neuroimmune Modulation: A New Paradigm in Autoimmune Treatment
For decades, autoimmune disease treatment has largely focused on suppressing the immune system with broad-spectrum medications.While frequently enough effective in managing symptoms, these therapies can come with significant side effects, leaving patients vulnerable to infection and other complications. Neuroimmune modulation offers a different path – one that aims to rebalance the immune system, rather than simply suppressing it.
The setpoint System is at the forefront of this revolution. This first-of-its-kind therapy utilizes targeted electrical stimulation of the vagus nerve, a crucial component of the autonomic nervous system. The vagus nerve acts as a bidirectional interaction pathway between the brain and the body, playing a critical role in regulating inflammation.
How does it work? By stimulating the vagus nerve, the SetPoint System influences the immune response, reducing the production of pro-inflammatory cytokines – the molecules that drive the chronic inflammation characteristic of autoimmune diseases like RA. This approach doesn’t simply mask symptoms; it addresses the underlying inflammatory processes.
Recent Research & Validation: A 2023 study published in Arthritis & Rheumatology demonstrated significant improvements in RA patients treated with the SetPoint System, including reductions in disease activity and pain levels. (Source: https://pubmed.ncbi.nlm.nih.gov/37215491/). Moreover, data presented at the american College of Rheumatology (ACR) Convergence 2023 conference highlighted the durability of these benefits, with sustained improvements observed over a 12-month period. (Source: https://www.setpointmedical.com/news/setpoint-medical-presents-positive-12-month-data-from-pivotal-clinical-trial-at-acr-convergence-2023/).
this isn’t just about RA either. SetPoint Medical is actively exploring the application of neuroimmune modulation to other autoimmune conditions, including Crohn’s disease, ulcerative colitis, and psoriasis. The potential to address a wide range of debilitating illnesses with a single, innovative platform is a game-changer.
Preparing for Launch: Building a Commercial Infrastructure
Securing funding is only the first step. SetPoint Medical is now laser-focused on preparing for the commercial launch of the SetPoint System, initially targeting select U.S. markets in 2024, with broader national expansion planned for 2026. to support this aspiring rollout,the company has made two key executive appointments:
erik Styacich,Vice President of Sales: Bringing a proven track record from valencia Technologies,Styacich will lead the sales strategy and execution.
Spencer Bailey, Vice President of Market Access & Reimbursement: Bailey’s expertise in navigating the complex landscape of market access and reimbursement, honed at neuromodulation leaders like MicroTransponder, Inc., will be crucial for ensuring patient access to this innovative therapy.
“We are pleased to share these strategic milestones underpinning our commitment to a successful and seamless market launch for the setpoint System in select U.S. markets this year, with broader national expansion in 2026,” stated Murthy V. Simhambhatla,Ph.D., CEO of SetPoint Medical. “We are thrilled to welcome an outstanding group of new investors to our exceptional syndicate.”